Uncommon indications in chronic pain for intrathecal drug delivery systems: a narrative review of the literature
Authors' conclusion
Based on limited evidence, IDDS may provide meaningful clinical benefit in patients with refractory uncommon pain syndromes.
Study context
- Population
- Patients with refractory uncommon chronic pain conditions (spinal cord injury-related pain, transverse myelitis, diabetic painful neuropathy, postherpetic neuralgia, craniofacial pain) treated with intrathecal drug delivery systems (IDDS)
- Outcome
- Efficacy and clinical utility of IDDS
Methodological detailsPubMed, Embase, Web of Science, CINAHL and Cochrane searched; reference lists manually screened; 3 reviewers screened using Covidence
- PubMed, Embase, Web of Science, CINAHL and Cochrane searched; reference lists manually screened; 3 reviewers screened using Covidence
Main finding
As reported in the abstract
- Evidence primarily from observational studies and small clinical trials
- IDDS may provide meaningful analgesia in carefully selected patients with central and peripheral pain, and facial neuropathic pain
- Magnitude of pain relief and durability of response variable
- Findings analysed narratively
Original publication
Uncommon indications in chronic pain for intrathecal drug delivery systems: a narrative review of the literature. Reg Anesth Pain Med. Published 8 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →